Ibaraki, Japan

Yukako Senga

This inventor holds 1 USPTO granted patent. Top assignee: National Institute of Advanced Industrial Science and Technology. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yukako Senga. Retrieved from https://idiyas.com/inventor/yukako-senga

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yukako Senga: Innovator in Polypeptide Aggregation Suppression

Introduction

Yukako Senga is a prominent inventor based in Ibaraki, Japan. She has made significant contributions to the field of biochemistry, particularly in the area of polypeptide aggregation. Her innovative work has led to the development of a method that addresses critical challenges in protein stability.

Latest Patents

Yukako Senga holds a patent for a method for suppressing aggregation of polypeptide. This invention specifically relates to a technique for preventing the formation of aggregates derived from antibodies or Fc region-containing proteins that possess non-native conformations. The method involves binding an AF.2A1 polypeptide or an analog to the aggregates in solution and subsequently collecting the bound aggregates.

Career Highlights

Yukako Senga is affiliated with the National Institute of Advanced Industrial Science and Technology, where she conducts her research. Her work has garnered attention for its potential applications in therapeutic protein development and biopharmaceuticals.

Collaborations

Yukako has collaborated with notable colleagues, including Hideki Watanabe and Shinya Honda, contributing to advancements in their shared field of research.

Conclusion

Yukako Senga's innovative approach to suppressing polypeptide aggregation represents a significant advancement in biochemistry. Her contributions are poised to impact the development of more stable therapeutic proteins, enhancing their efficacy and safety.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…